May 6, 2026
Australia's assistive technology market is one of the most structurally interesting consumer sectors in the Asia-Pacific region. It is large, growing, government-funded in significant part, and chronically underserved by the kind of accessible, well-designed technology products that have transformed adjacent categories. For international technology brands with products that could genuinely improve the lives of people with disability, older Australians, or students with additional learning needs, the opportunity is real - and the barriers, while genuine, are navigable with the right local partner.
This piece is written for brand owners and investors who are unfamiliar with the Australian AT landscape. It explains how the market works, who buys assistive technology and how they fund it, where the growth is coming from, and what it actually takes to succeed here.
Assistive technology in Australia is purchased across five distinct funding and channel environments, each with its own decision-making process, compliance requirements, and customer relationship dynamics. Understanding this structure is essential for any brand considering market entry - because a product that is perfectly positioned for one channel may be completely invisible in another.
NDIS - National Disability Insurance Scheme
Australia's landmark disability support scheme funds assistive technology for eligible participants. Purchasing decisions involve the participant, their support coordinator or plan manager, and often a prescribing therapist. Products must meet AT registration requirements and pricing benchmarks. The scheme currently supports over 600,000 Australians.
Education
Schools, universities, and specialist education providers purchase AT for students with disability, learning differences, and additional needs. Purchasing is driven by teachers, learning support teams, and occupational therapists. Both government and independent school sectors are active buyers, with separate funding pathways.
Aged care
Australia's ageing population is driving rapid growth in the aged care AT segment. Funding flows through the Support at Home programme (currently transitioning in 2026), the Commonwealth Home Support Programme, and residential aged care facilities. Medical insurers are also an increasingly active funding pathway for preventive and rehabilitation AT.
Healthcare and medical insurers
Hospitals, rehabilitation centres, and allied health clinics purchase AT for clinical use and patient discharge planning. Private health insurers fund AT through extras cover and post-acute care programmes. This channel is particularly relevant for products with a clinical evidence base or rehabilitation application.
Direct / retail
A growing proportion of AT purchases are self-funded by individuals, families, and carers who either do not qualify for scheme funding or prefer the simplicity of a direct purchase. This segment responds well to accessible product information, strong customer support, and fast fulfilment.
Of all the growth vectors in Australian AT, aged care is the most significant. Australia's population is ageing faster than at any point in the country's history. The number of Australians aged 65 and over is projected to nearly double by 2060. That demographic shift is creating sustained, structural demand for products that support independence, safety, communication, and daily living - across virtually every assistive technology category.
The 2026 transition to the Support at Home programme - currently underway - is creating a more consumer-directed funding model for older Australians, one where individuals and families have greater discretion over how their care budget is spent. This is materially positive for AT brands, because it shifts purchasing decisions closer to the end user and creates a retail-style demand environment within what has historically been a purely clinical channel.
The most common mistake international AT brands make when evaluating the Australian market is assuming the barrier is regulatory. In reality, the primary barrier is navigational. The Australian AT market is not difficult to enter because of product standards - it is difficult to enter because the funding and procurement systems are complex, the decision-making chains are long, and the professional relationships that drive prescribing and purchasing behaviour take time to build.
An occupational therapist recommending a product to an NDIS participant needs to justify that recommendation against a funding framework. A school learning support coordinator purchasing technology for a student needs to navigate the relevant state education department's procurement process. A hospital discharge planner recommending AT needs to work within a clinical evidence framework. In each case, the brand is one step removed from the purchasing decision - and the intermediary needs to trust both the product and the supplier.
This is why digital platform capability matters as much as product quality in this market. Assistive Tech has built customer-facing tools that help clients, carers, and professionals navigate funding options, identify eligible products, and complete the documentation required for funded purchases. That infrastructure reduces friction for the intermediaries who drive purchasing decisions - and it is the kind of capability that takes years to build and cannot be replicated quickly by a new market entrant.
Through Assistive Tech, The Glue Group has built deep domain expertise across every channel in the Australian AT market. We hold NDIS registration, maintain active relationships with occupational therapists, speech pathologists, and learning support professionals across the country, and operate digital platforms designed specifically for the complexity of funded AT purchasing.
For international brands with products relevant to disability, ageing, education, or healthcare, this represents an entry point into a market that would otherwise take years to develop independently. We understand how each funding channel works, which professional communities influence purchasing in each segment, and how to position a product credibly across the clinical, educational, and consumer dimensions of the AT market simultaneously.
If you have a product with genuine AT applications and you are evaluating the Australian and New Zealand market, we would welcome a direct conversation.